Cover Image
市場調查報告書

市場預測自體免疫溶血性貧血 (AIHA)的主要8個國家

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 363599
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
市場預測自體免疫溶血性貧血 (AIHA)的主要8個國家 Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026
出版日期: 2016年07月01日 內容資訊: 英文 48 Pages
簡介

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、巴西、日本) 的自體免疫溶血性貧血 (AIHA)的目前患者數 (性別,各年齡世代) 的調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷預後,主要的提供著症狀和併發症等系統性資訊。

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

AIHA臨床管理

  • AIHA的輸血療法

疾病相關的主要併發症/特徵

定量化做患者數的手法

自體免疫溶血性貧血 (AIHA)的最大患病人數

自體免疫溶血性貧血 (AIHA) 患者的亞型

  • 溫式自體免疫溶血性貧血 (AIHA) 患者
  • 冷式自體免疫溶血性貧血 (AIHA) 患者
  • 混合式自體免疫溶血性貧血 (AIHA) 患者

自體免疫溶血性貧血 (AIHA)的市場預測

  • 溫式、混合式AIHA中的第一治療選項
  • 溫式、混合式AIHA的第二治療選項
  • 冷式AIHA中的第一治療選項
  • 冷式AIHA的第二治療選項
  • AIHA的輸血的必要條件

預測的調查手法 圖表

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

價格的線上資料、平台

參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: AIHA0010716

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

  • Lymphoproliferative conditions:
    • CLL
    • HL
    • NHL
  • Myeloproliferative conditions:
    • Multiple myeloma
    • Myelofibrosis
    • MGUS
  • Autoimmune conditions:
    • RA
    • SLE
    • Polyarteritis nodosa
  • Infections:
    • Pneumonia & Tuberculosis
    • Syphilis
    • Epstein-Barr
    • Chronic active hepatitis
    • Mononucleosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.
  • Identify sub-populations within AIHA which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AIHA patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Clinical Management of AIHA
    • Transfusion therapy in AIHA
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for AIHA
  • Subtypes of AIHA patients
    • Warm AIHA patients
    • Cold AIHA patients
    • Mixed-type AIHA patients
  • Market Forecast for AIHA
    • 1st Line Treatment Options within Warm & Mixed-type AIHA
    • 2nd Line Treatment Options within Warm & Mixed-type AIHA
    • 1st Line Treatment Options within Cold AIHA
    • 2nd Line Treatment Options within Cold AIHA
    • Requirement for Blood Transfusions within AIHA
  • Methodology for Forecast Figures
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Drugs implicated in development of AIHA
  • Tests for AIHA and expected findings in haemolysis
  • Classification of AIHA
  • Treatment options for warm AIHA
  • Treatment options for cold AIHA
  • Incidence of AIHA, total (000s)
  • Incidence of AIHA, males (000s)
  • Incidence of AIHA, females (000s)
  • Incident AIHA by main sub-type, total (000s)
  • Incident Warm AIHA by cause, total (000s)
  • Warm Secondary AIHA by main aetiology, total (000s)
  • Incident Cold AIHA by main type, total (000s)
  • Incident CAS AIHA by cause, total (000s)
  • CAS Secondary AIHA by main aetiology, total (000s)
  • Incident Mixed-type AIHA by cause, total (000s)
  • Mixed-type Secondary AIHA by main aetiology, total (000s)
  • Prednisolone estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Splenectomy estimated forecast 2nd line, Patients (000s)
  • Rituximab estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Transfusion estimated forecast, Patients (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of AIHA by 5-yr age cohort, males (000s)
  • USA Incidence of AIHA by 5-yr age cohort, females (000s)
  • France Incidence of AIHA by 5-yr age cohort, males (000s)
  • France Incidence of AIHA by 5-yr age cohort, females (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, males (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, females (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, males (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, females (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, males (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, females (000s)
  • UK Incidence of AIHA by 5-yr age cohort, males (000s)
  • UK Incidence of AIHA by 5-yr age cohort, females (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, males (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, females (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, males (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, females (000s)
Back to Top